Category Archives: Business of Biotech

SBIR Reauthorization Moves Forward

SBIR Reauthorization Moves Forward

NIH has reissued its Small Business Innovation Research (SBIR) Omnibus Grant Solicitation announcement, which states that small businesses that are majority-owned by multiple venture capital operating companies are eligible to apply for (1) these SBIR grants and (2) any other NIH SBIR funding opportunities announced after January 28, 2013.  The NIH grant solicitation announcement can be found here. With this re-issuance, small businesses that are majority-owned by multiple venture capital operating companies (VCOCs), hedge funds Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

Announcing the Business Solutions Raffle at the BIO International Convention

BIO-Business-Solutions-Tagline

BIO Partner Pavilion Raffle Did you know that BIO offers a variety of preferred suppliers with discounted products and services to its members and 43 state and regional biotech associations through its Business Solutions cost-savings program? With nearly 3,000 participating companies nationwide, BIO is considered a one stop shop for advocacy, business development and cost-savings. Want to learn how to get more bang for your buck while betting against your odds in a raffle drawing? Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor Conference

Fireside Chat

Like a number of companies, Eli Lilly is confronting a wave of patent expirations called the patent cliff. The company lost U.S. patent protection on the anti-psychotic Zyprexa in the fall of 2011 and they’re facing the losses of the antidepressant Cymbalta in December of 2013 and the osteoporosis drug Evista in 2014. The loss of protection endangers the company’s ability to profit from the drugs and they could face a $25 billion loss in Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Celgene CEO on New Multiple Myeloma Drug Approvals

BIO CEO

Following on the heels of two big announcements in February, Celgene CEO Robert Hugin (one of FierceBiotech’s most influential people in biopharma) participated in a fireside chat with Joel Sendek, managing director and biotechnology analyst at Stifel Nicolaus & Company, at the 15th Annual BIO CEO & Investor Conference in New York. First, on Friday, February 8, the Food and Drug Administration (FDA) approved Celgene’s drug Pomalyst for patients with multiple myeloma whose disease has Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Beantown Biotech: ‘Dominant Life Sciences Cluster’

Boston

Massachusetts’ Secretary of Housing and Economic Development, Greg Bialecki, was quoted in today’s Boston Herald as saying: “We are the dominant life sciences cluster in the world,” Greg Bialecki said, “and I don’t think that was an accident.” Thanks to the Gov. Deval Patrick administration’s support for bioscience economic development, his state has continued to grow and add biotech industry jobs as an economic engine. Boston’s  biopharm industry is comprised of more than 500 companies Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,